Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 5, Issue 3, 2015, Pages

  Collette, Y ^a   Prebet T ^a,b   Goubard, A ^a   Adelaide J ^a   Castellano, R ^a   Carbuccia, N ^a   Garnier, S ^a   Guille, A ^a   Arnoulet, C ^a,b   Charbonier, A ^a,b   Mozziconacci, M J ^a,b   Birnbaum, D ^a   Chaffanet, M ^a   Vey, N ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD19 ANTIGEN; CD20 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DASATINIB; DEXAMETHASONE; ETOPOSIDE; MITOXANTRONE; NILOTINIB; PONATINIB; STEROID; VINCRISTINE; IMIDAZOLE DERIVATIVE; PHARMACOLOGICAL BIOMARKER; PYRIDAZINE DERIVATIVE; RCSD1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ABL1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 1Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION; CLONAL EVOLUTION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; EC50; EX VIVO STUDY; EXON; FATIGUE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LEUKEMIA CELL; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; PREDICTION; RCSD1 GENE; REAL TIME POLYMERASE CHAIN REACTION; REDUCED INTENSITY CONDITIONING; SEPTIC SHOCK; CHROMOSOME 1; CHROMOSOME 9; GENE TRANSLOCATION; GENETICS; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ADULT; BIOMARKERS, PHARMACOLOGICAL; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIDAZINES; TRANSLOCATION, GENETIC;

EID: 84989360897     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.13     Document Type: Letter

References (11)

1. Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, Almqvist A, Lundan T et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapyrefractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009; 94: 1469-1471.
2. Inokuchi K, Wakita S, Hirakawa T, Tamai H, Yokose N, Yamaguchi H et al. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. Int J Hematol 2011; 94: 255-260.
3. De Braekeleer E, Douet-Guilbert N, Guardiola P, Rowe D, Mustjoki S, Zamecnikova A et al. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion. Leukemia 2013; 27: 1422-1424.
4. Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L et al. Therapeutic targeting of c-Myc in T-cell acute lymphobalstic leukemia, T-ALL. Oncotarget 2014; 5: 3168-3172.
5. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 2013; 27: 32-40.
6. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-2088.
7. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
8. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J et al. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1-11.
9. Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E et al. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 2008; 134: 793-803.
10. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 12: 1416-1429.
11. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D et al. Targetable kinase-Activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015.